Literature DB >> 33946899

Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection.

Francesco Ardito1,2, Francesco Razionale1, Lisa Salvatore3, Tonia Cenci4, Maria Vellone1,2, Michele Basso3, Elena Panettieri1, Maria Alessandra Calegari3, Giampaolo Tortora2,3, Maurizio Martini4, Felice Giuliante1,2.   

Abstract

If KRAS mutation status of primary colorectal tumor is representative of corresponding colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess the incidence of discordance and its impact on overall survival (OS) in a homogenous group of patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate was 15.9%. Its incidence varied according to the time interval between the two mutation analyses (p = 0.025; Pearson correlation = 0.2) and it was significantly higher during the first 6 months from the time of primary tumor evaluation. On multivariable analysis, type of discordance (wild-type in primary tumor, mutation in CRLM) was the strongest predictor of poor OS (p < 0.001). At multivariable logistic regression analysis, the number of CRLM >3 was an independent risk factor for the risk of KRAS discordance associated with the worst prognosis (OR = 4.600; p = 0.047). Results of our study suggested that, in the era of precision medicine, possibility of KRAS discordance should be taken into account within multidisciplinary management of patients with metastatic colorectal cancer.

Entities:  

Keywords:  KRAS discordance; KRAS mutation status; colorectal liver metastases; colorectal tumor; overall survival; precision medicine

Year:  2021        PMID: 33946899     DOI: 10.3390/cancers13092148

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  41 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

2.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

3.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

Review 4.  Biomarkers in colorectal liver metastases.

Authors:  S Yamashita; Y S Chun; S E Kopetz; J-N Vauthey
Journal:  Br J Surg       Date:  2018-03-26       Impact factor: 6.939

5.  Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection.

Authors:  Robbert J de Haas; Dennis A Wicherts; Paola Andreani; Gérard Pascal; Faouzi Saliba; Philippe Ichai; René Adam; Denis Castaing; Daniel Azoulay
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

6.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

Authors:  Daniele Santini; Fotios Loupakis; Bruno Vincenzi; Irene Floriani; Irene Stasi; Emanuele Canestrari; Eliana Rulli; Paolo Enrico Maltese; Francesca Andreoni; Gianluca Masi; Francesco Graziano; Giacomo Giulio Baldi; Lisa Salvatore; Antonio Russo; Giuseppe Perrone; Maria Rosa Tommasino; Mauro Magnani; Alfredo Falcone; Giuseppe Tonini; Annamaria Ruzzo
Journal:  Oncologist       Date:  2008-12-04

7.  Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas.

Authors:  P Zauber; M Sabbath-Solitare; S P Marotta; D T Bishop
Journal:  Mol Pathol       Date:  2003-06

8.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

9.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.

Authors:  John A Bridgewater; Siân A Pugh; Tom Maishman; Zina Eminton; Jane Mellor; Amy Whitehead; Louise Stanton; Michael Radford; Andrea Corkhill; Gareth O Griffiths; Stephen Falk; Juan W Valle; Derek O'Reilly; Ajith K Siriwardena; Joanne Hornbuckle; Myrddin Rees; Timothy J Iveson; Tamas Hickish; O James Garden; David Cunningham; Timothy S Maughan; John N Primrose
Journal:  Lancet Oncol       Date:  2020-01-31       Impact factor: 41.316

Review 10.  Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

Authors:  Richard M Goldberg; Clara Montagut; Zev A Wainberg; Philippe Ronga; François Audhuy; Julien Taieb; Sebastian Stintzing; Salvatore Siena; Daniele Santini
Journal:  ESMO Open       Date:  2018-05-05
View more
  1 in total

1.  Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).

Authors:  Ruba A Hamed; Sam Marks; Helen Mcelligott; Roshni Kalachand; Hawa Ibrahim; Said Atyani; Greg Korpanty; Nemer Osman
Journal:  Mol Clin Oncol       Date:  2021-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.